Literature DB >> 26100031

Comparison of microporous polysaccharide hemospheres and Ankaferd Blood Stopper in a rabbit epistaxis model.

Veysel Yurttas1, Murat Sereflican2, Elçin Hakan Terzi3, Gulzade Ozyalvaçlı4, Hasan Kazaz5.   

Abstract

The aim of this study was to evaluate the histopathological impact, effectiveness, and safety of two hemostatic agents, Ankaferd Blood Stopper (ABS) and microporous polysaccharide hemospheres (MPH), in an experimental rabbit epistaxis model. Rabbits were randomly assigned, using a computerized random number generator, to the following three groups of six animals: group 1 (control, irrigated with saline); group 2 (ABS-treated); and group 3 (MPH-treated). In all groups, a standardized rabbit epistaxis model was used. Hemostasis time and extent of nasal bleeding were measured to compare the hemostatic effect of ABS and MPH among groups. Septums were removed for histopathological analysis, 7 days after the procedure. ABS reduced hemostasis time to 104.2 s and amount of bleeding to 20.5 mg. MPH reduced hemostasis time to 71.7 s and amount of bleeding to 11.5 mg. Mean bleeding time in wounds administered ABS and MPH was significantly shorter compared with wounds administered isotonic saline solution (p = 0.004). ABS and MPH application decreased bleeding significantly compared with the control group (p = 0.004). Bleeding time and amount in the MPH group was significantly reduced compared with the ABS group (p = 0.013 and p = 0.004, respectively). There was no significant difference in the histopathological evaluation results between the ABS, MPH, and control groups. Our data indicate that both ABS and MPH represent safe, effective, and fast-acting hemostatic agents in the management of epistaxis. MPH was more effective than ABS in terms of hemostasis time and amount of bleeding.

Entities:  

Keywords:  Ankaferd Blood Stopper; Epistaxis treatment; Histopathology; Microporous polysaccharide hemospheres

Mesh:

Substances:

Year:  2015        PMID: 26100031     DOI: 10.1007/s00405-015-3692-8

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  23 in total

1.  The efficacy of Ankaferd Blood Stopper in heparin-induced hemostatic abnormality in a rat epistaxis model.

Authors:  Ismail Iynen; Ozgur Sogut; Rustu Kose
Journal:  Otolaryngol Head Neck Surg       Date:  2011-07-12       Impact factor: 3.497

2.  Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper.

Authors:  H Goker; I C Haznedaroglu; S Ercetin; S Kirazli; U Akman; Y Ozturk; H C Firat
Journal:  J Int Med Res       Date:  2008 Jan-Feb       Impact factor: 1.671

Review 3.  Endovascular treatment of epistaxis.

Authors:  P W A Willems; R I Farb; R Agid
Journal:  AJNR Am J Neuroradiol       Date:  2009-04-16       Impact factor: 3.825

4.  Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in patients with acute anterior epistaxis.

Authors:  Ronald A Mathiasen; Raul M Cruz
Journal:  Laryngoscope       Date:  2005-05       Impact factor: 3.325

5.  Radiological and histopathological comparison of microporous polysaccharide hemospheres and oxidized regenerated cellulose in the rabbit brain: a study of efficacy and safety.

Authors:  Hakan Emmez; Mehmet Tonge; Nil Tokgoz; Emre Durdag; Ipek Gonul; Necdet Cevıker
Journal:  Turk Neurosurg       Date:  2010-10       Impact factor: 1.003

6.  Prospective, randomized, controlled clinical trial of Ankaferd Blood Stopper in patients with acute anterior epistaxis.

Authors:  Aysenur Meric Teker; Arzu Yasemin Korkut; Volkan Kahya; Orhan Gedikli
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-02-13       Impact factor: 2.503

7.  Predominant pathogens in hospital infections.

Authors:  W R Jarvis; W J Martone
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

8.  Comparative safety and efficacy of topical hemostatic agents in a rat neurosurgical model.

Authors:  Mark H Ereth; Matthew Schaff; Eric F Ericson; Nicholas M Wetjen; Gregory A Nuttall; William C Oliver
Journal:  Neurosurgery       Date:  2008-10       Impact factor: 4.654

9.  The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model.

Authors:  Ali Kosar; Handan S Cipil; Arif Kaya; Burak Uz; Ibrahim C Haznedaroglu; Hakan Goker; Oktay Ozdemir; Sevil Ercetin; Serafettin Kirazli; Huseyin Cahit Firat
Journal:  Blood Coagul Fibrinolysis       Date:  2009-04       Impact factor: 1.276

Review 10.  Epistaxis.

Authors:  Thomas O Gifford; Richard R Orlandi
Journal:  Otolaryngol Clin North Am       Date:  2008-06       Impact factor: 3.346

View more
  1 in total

1.  Green hemostatic sponge-like scaffold composed of soy protein and chitin for the treatment of epistaxis.

Authors:  Jon Jimenez-Martin; Kevin Las Heras; Alaitz Etxabide; Jone Uranga; Koro de la Caba; Pedro Guerrero; Manoli Igartua; Edorta Santos-Vizcaino; Rosa Maria Hernandez
Journal:  Mater Today Bio       Date:  2022-04-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.